Neuroprotection and stroke: time for a compromise.

Area of Science:

• Neuroscience
• Clinical Trials
• Pharmacology

Background:

• A review of 286 acute ischemic stroke trials revealed 209 completed trials with limited evidence of patient benefit.
• The modest success of tissue plasminogen activator (tPA) studies contrasts with the failure of many other interventions.

Purpose of the Study:

• To examine potential weaknesses in the selection process for pharmacological agents in stroke clinical trials.
• To understand why neuroprotective drugs effective in pre-clinical studies have not translated to clinical success in stroke.

Main Methods:

• Literature review of completed and ongoing acute ischemic stroke trials.
• Analysis of the criteria used for selecting drug candidates for clinical investigation.
• Evaluation of the translation from pre-clinical efficacy to clinical outcomes in stroke.

Main Results:

• A significant number of completed stroke trials did not demonstrate clear patient benefit.
• Questions arise regarding the sole reliance on pre-clinical efficacy for selecting drugs for clinical trials.
• Potential flaws in research and clinical practices may hinder achieving brain protection in stroke.

Conclusions:

• The selection of neuroprotective agents for acute ischemic stroke trials may be flawed.
• Weaknesses in the research and clinical approach contribute to the lack of successful brain protection strategies.
• Further investigation into trial design and drug selection is crucial for advancing stroke treatment.